Prostate Cancer Precision Diagnosis
At Fosun Health, prostate cancer diagnosis is not just about “finding cancer”—it is about distinguishing aggressive tumors from indolent ones, mapping the cancer’s exact location, and designing a plan that preserves your urinary control and sexual function. Our streamlined pathway delivers answers within days:
We measure total and free PSA, along with PSA density and velocity. For borderline results, we use PHI (Prostate Health Index) or 4Kscore to improve specificity and reduce unnecessary biopsies.
- Multi-Parametric MRI (mpMRI): The gold standard for prostate imaging. It reveals tumor location, size, extracapsular extension, and seminal vesicle invasion—critical for staging and biopsy planning. PI-RADS score guides clinical decision-making.
- PSMA PET-CT / PSMA PET-CT: Detects lymph node and distant metastases with exceptional accuracy—essential for high-risk patients and recurrence detection.
- MRI-Targeted Fusion Biopsy: We fuse mpMRI images with real-time ultrasound to sample only suspicious areas, reducing the detection of insignificant cancers and avoiding unnecessary diagnosis of indolent disease. Transperineal approach lowers infection risk.
- Systematic Biopsy: Performed alongside targeted biopsy for a complete assessment.
- PSMA PET-CT: Replaces conventional CT and bone scan for accurate staging.
- Bone Scan (if PSMA not available): Detects skeletal metastases.
Using NGS (Next-Generation Sequencing), we analyze androgen receptor (AR) mutations, BRCA1/2, ATM, PALB2, MSI/dMMR, TMB, NTRK fusions, and over 300 cancer-related genes. This determines whether your tumor will respond to PARP inhibitors (for BRCA mutations), immunotherapy (for MSI-H/dMMR), or targeted therapies—and guides prognosis. For patients considering active surveillance, genomic classifiers (Decipher, Oncotype DX GPS) help predict tumor aggressiveness, ensuring you are not over-treated or under-treated.
